Matrix metalloproteinase inhibitors 1998
- 1 March 1998
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 8 (3), 259-282
- https://doi.org/10.1517/13543776.8.3.259
Abstract
Inhibition of matrix metalloproteinases (MMPs) as an approach to treatment of diseases such as cancer, arthritis and multiple sclerosis (MS) is now an area of intense interest within the pharmaceutical industry. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1996.Keywords
This publication has 56 references indexed in Scilit:
- Inhibitory effect on HT-1080 tumor cell invasion in vitro using 9-(2′-hydroxyethyl)adenine 2′-phosphatesBioorganic & Medicinal Chemistry Letters, 1997
- Solid-phase synthesis of a N-carboxyalkyl tripeptide combinatorial libraryBioorganic & Medicinal Chemistry Letters, 1997
- Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)Bioorganic & Medicinal Chemistry Letters, 1997
- Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide librariesMolecular Diversity, 1997
- Inhibition of Stromelysin-1 (MMP-3) by P1‘-Biphenylylethyl Carboxyalkyl DipeptidesJournal of Medicinal Chemistry, 1997
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistryBioorganic & Medicinal Chemistry Letters, 1996
- Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate seriesBioorganic & Medicinal Chemistry Letters, 1996
- Synthesis and Structure-Activity Relationships of Gelatinase Inhibitors Derived from Matlystatins.CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
- Steric inhibition of hydrogen-bonding in a secondary amideSpectrochimica Acta, 1964